You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/74912
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCastellano, O.-
dc.contributor.authorArji, M.-
dc.contributor.authorSancho, C.-
dc.contributor.authorCarro, J.-
dc.contributor.authorRiolobos, A. S.-
dc.contributor.authorMolina, V.-
dc.contributor.authorGómez-Nieto, R.-
dc.contributor.authorde Anchieta de Castro e Horta, José-
dc.contributor.authorHerrero-Turrión, M. J.-
dc.contributor.authorLópez, D. E.-
dc.date.accessioned2014-05-27T11:28:44Z-
dc.date.accessioned2016-10-25T18:45:59Z-
dc.date.available2014-05-27T11:28:44Z-
dc.date.available2016-10-25T18:45:59Z-
dc.date.issued2013-04-01-
dc.identifierhttp://dx.doi.org/10.1016/j.bbr.2012.12.036-
dc.identifier.citationBehavioural Brain Research, v. 242, n. 1, p. 178-190, 2013.-
dc.identifier.issn0166-4328-
dc.identifier.issn1872-7549-
dc.identifier.urihttp://hdl.handle.net/11449/74912-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/74912-
dc.description.abstractIn the present work we analyzed the effect of the chronic administration of risperidone (2mg/kg over 65 days) on behavioural, morphological and molecular aspects in an experimental model of schizophrenia obtained by bilateral injection of ibotenic acid into the ventral hippocampus of new-born rats. Our results show that during their adult lives the animals with hippocampal lesions exhibit different alterations, mainly at behavioural level and in the gene expression of dopamine D2 and 5-HT2A receptors. However, at morphological level the study performed on the prefrontal cortex did not reveal any alterations in either the thickness or the number of cells immunoreactive for c-Fos, GFAP, CBP or PV. Overall, risperidone administration elicited a trend towards the recovery of the values previously altered by the hippocampal lesion, approaching the values seen in the animals without lesions. It may be concluded that the administration of risperidone in the schizophrenia model employed helps to improve the altered functions, with no significant negative effects. © 2013.en
dc.format.extent178-190-
dc.language.isoeng-
dc.sourceScopus-
dc.subject5-HT receptor-
dc.subjectAntipsychotic drugs-
dc.subjectBehaviour-
dc.subjectDA receptor-
dc.subjectImmunohistochemistry-
dc.subjectPrefrontal cortex-
dc.subjectRisperidone-
dc.subjectSchizophrenia-
dc.subjectcalbindin-
dc.subjectdopamine 2 receptor-
dc.subjectglial fibrillary acidic protein-
dc.subjectibotenic acid-
dc.subjectparvalbumin-
dc.subjectprotein c fos-
dc.subjectrisperidone-
dc.subjectserotonin 2A receptor-
dc.subjectadult animal-
dc.subjectanimal behavior-
dc.subjectanimal experiment-
dc.subjectanimal model-
dc.subjectanimal tissue-
dc.subjectbrain damage-
dc.subjectcell count-
dc.subjectchronic drug administration-
dc.subjectcontrolled study-
dc.subjectcortical thickness (brain)-
dc.subjectdisease model-
dc.subjectgene expression-
dc.subjecthippocampus-
dc.subjectimmunoreactivity-
dc.subjectnewborn-
dc.subjectnonhuman-
dc.subjectnucleotide sequence-
dc.subjectprefrontal cortex-
dc.subjectpriority journal-
dc.subjectrat-
dc.subjectschizophrenia-
dc.subjectAge Factors-
dc.subjectAnimals-
dc.subjectAnimals, Newborn-
dc.subjectAntipsychotic Agents-
dc.subjectAvoidance Learning-
dc.subjectBehavior, Animal-
dc.subjectBrain-
dc.subjectCell Count-
dc.subjectCREB-Binding Protein-
dc.subjectDisease Models, Animal-
dc.subjectDrug Administration Schedule-
dc.subjectExcitatory Amino Acid Agonists-
dc.subjectExploratory Behavior-
dc.subjectFemale-
dc.subjectGene Expression Regulation-
dc.subjectGlial Fibrillary Acidic Protein-
dc.subjectGrooming-
dc.subjectHippocampus-
dc.subjectIbotenic Acid-
dc.subjectMale-
dc.subjectParvalbumins-
dc.subjectProto-Oncogene Proteins c-fos-
dc.subjectRats-
dc.subjectRats, Wistar-
dc.subjectReceptor, Serotonin, 5-HT2A-
dc.subjectReceptors, Dopamine D2-
dc.titleChronic administration of risperidone in a rat model of schizophrenia: A behavioural, morphological and molecular studyen
dc.typeoutro-
dc.contributor.institutionInstitute for Neuroscience of Castilla y León-
dc.contributor.institutionUniversity of Salamanca-
dc.contributor.institutionUniversity of Valladolid-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationInstitute for Neuroscience of Castilla y León, Salamanca-
dc.description.affiliationDepartment of Cell Biology and Pathology University of Salamanca, Salamanca-
dc.description.affiliationDepartment of Physiology and Pharmacology University of Salamanca, Salamanca-
dc.description.affiliationDepartment of Basic Psychology, Psychobiology and Methodology University of Salamanca, Salamanca-
dc.description.affiliationDepartment of Psychiatry School of Medicine University of Valladolid-
dc.description.affiliationInstitute of Biomedical Research of Salamanca (IBSAL) University of Salamanca, Salamanca-
dc.description.affiliationBiosciences Institute São Paulo State University (UNESP), Campus of Botucatu-
dc.description.affiliationUnespBiosciences Institute São Paulo State University (UNESP), Campus of Botucatu-
dc.identifier.doi10.1016/j.bbr.2012.12.036-
dc.identifier.wosWOS:000315660100022-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofBehavioural Brain Research-
dc.identifier.scopus2-s2.0-84872578236-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.